Provided by Tiger Trade Technology Pte. Ltd.

Adagene

2.93
-0.2700-8.44%
Post-market: 2.960.0300+1.02%19:30 EDT
Volume:278.28K
Turnover:832.16K
Market Cap:196.73M
PE:-7.77
High:3.12
Open:3.12
Low:2.92
Close:3.20
52wk High:4.85
52wk Low:1.30
Shares:67.14M
Float Shares:42.20M
Volume Ratio:0.78
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3773
EPS(LYR):-0.3750
ROE:-28.50%
ROA:-13.95%
PB:2.20
PE(LYR):-7.81

Loading ...

Adagene Management Attends Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Aug 20

Adagene to Participate in Three Upcoming Investor Conferences

GlobeNewswire
·
Aug 20

Adagene Director Cuong Do Reports Purchase of ADS Worth $7,500

Reuters
·
Aug 19

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Natera (NTRA)

TIPRANKS
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)

TIPRANKS
·
Aug 13

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 13

Adagene FY26 H1 Net Loss Widens to US$ 16.4 Million; Revenue Turns to US$ 1.6 Million

Reuters
·
Aug 12

Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M

Benzinga Earnings
·
Aug 12

Press Release: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
Aug 12

Adagene Inc. Expected to Post a Loss of 10 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Adagene CEO Peter Luo Buys 23,245 ADS Worth $84,763.97

Reuters
·
Aug 07

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 14

Adagene Posts Investor Presentation Highlighting Adg126 Masked Anti-ctla-4 Program in MSS Colorectal Cancer

Reuters
·
Jul 07

Adagene joins Stifel Annual Virtual Oncology Event for fireside chat, investor meetings

Reuters
·
May 12

Adagene to Participate in Two Upcoming Investor Conferences

GlobeNewswire
·
May 12

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)

TIPRANKS
·
May 03

Analyst Initiates Buy on Muza Developer, Citing Promising MSS CRC Data, Clear Registrational Path, and Broader Expansion Upside Despite Cash Constraints

TIPRANKS
·
Apr 27

Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers

TIPRANKS
·
Apr 18

Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR

TIPRANKS
·
Apr 18

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

GlobeNewswire
·
Apr 18